WO2007125946A1 - ペプチド - Google Patents
ペプチド Download PDFInfo
- Publication number
- WO2007125946A1 WO2007125946A1 PCT/JP2007/058926 JP2007058926W WO2007125946A1 WO 2007125946 A1 WO2007125946 A1 WO 2007125946A1 JP 2007058926 W JP2007058926 W JP 2007058926W WO 2007125946 A1 WO2007125946 A1 WO 2007125946A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- cheese
- pro
- adiponectin
- gin
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 164
- 108010076365 Adiponectin Proteins 0.000 claims abstract description 111
- 102000011690 Adiponectin Human genes 0.000 claims abstract description 111
- 235000013351 cheese Nutrition 0.000 claims abstract description 99
- 239000008280 blood Substances 0.000 claims abstract description 61
- 210000004369 blood Anatomy 0.000 claims abstract description 61
- 230000007423 decrease Effects 0.000 claims abstract description 49
- 238000004519 manufacturing process Methods 0.000 claims abstract description 49
- 235000013305 food Nutrition 0.000 claims abstract description 45
- 230000001737 promoting effect Effects 0.000 claims abstract description 45
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 42
- 239000004480 active ingredient Substances 0.000 claims abstract description 28
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 16
- 235000013361 beverage Nutrition 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 230000009471 action Effects 0.000 claims description 18
- 239000004615 ingredient Substances 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 102000014171 Milk Proteins Human genes 0.000 claims description 8
- 108010011756 Milk Proteins Proteins 0.000 claims description 8
- 235000021239 milk protein Nutrition 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 230000001629 suppression Effects 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 40
- 230000003405 preventing effect Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- FJLODLCIOJUDRG-PYJNHQTQSA-N Pro-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 FJLODLCIOJUDRG-PYJNHQTQSA-N 0.000 abstract description 2
- 239000003925 fat Substances 0.000 description 35
- 150000001413 amino acids Chemical group 0.000 description 32
- 235000019197 fats Nutrition 0.000 description 32
- 235000013350 formula milk Nutrition 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 25
- 239000000243 solution Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 230000001458 anti-acid effect Effects 0.000 description 16
- 102000004142 Trypsin Human genes 0.000 description 15
- 108090000631 Trypsin Proteins 0.000 description 15
- 239000012588 trypsin Substances 0.000 description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 210000001789 adipocyte Anatomy 0.000 description 13
- 235000006708 antioxidants Nutrition 0.000 description 13
- 239000000306 component Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 101800000068 Antioxidant peptide Proteins 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 10
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 10
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 9
- 210000001596 intra-abdominal fat Anatomy 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 208000001145 Metabolic Syndrome Diseases 0.000 description 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 8
- 210000000577 adipose tissue Anatomy 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 206010003210 Arteriosclerosis Diseases 0.000 description 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 235000020940 control diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000020778 linoleic acid Nutrition 0.000 description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 5
- 108010087806 Carnosine Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 229940044199 carnosine Drugs 0.000 description 5
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 5
- 230000002124 endocrine Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 235000015203 fruit juice Nutrition 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000014214 soft drink Nutrition 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000012970 cakes Nutrition 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 150000001746 carotenes Chemical class 0.000 description 3
- 235000005473 carotenes Nutrition 0.000 description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 3
- 235000005487 catechin Nutrition 0.000 description 3
- 229950001002 cianidanol Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 238000005238 degreasing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- -1 hydrated peroxides Chemical class 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 210000000229 preadipocyte Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 238000013382 DNA quantification Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000040739 Secretory proteins Human genes 0.000 description 2
- 108091058545 Secretory proteins Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000011481 absorbance measurement Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 239000005428 food component Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000014059 processed cheese Nutrition 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AGTWOFLOEJZCKI-UHFFFAOYSA-N ethane-1,2-dithiol;phenol Chemical compound SCCS.OC1=CC=CC=C1 AGTWOFLOEJZCKI-UHFFFAOYSA-N 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000021116 parmesan Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 108700002051 rat Adipoq Proteins 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/24—Organic nitrogen compounds
- A21D2/26—Proteins
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/24—Organic nitrogen compounds
- A21D2/26—Proteins
- A21D2/268—Hydrolysates from proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/068—Particular types of cheese
- A23C19/08—Process cheese preparations; Making thereof, e.g. melting, emulsifying, sterilizing
- A23C19/082—Adding substances to the curd before or during melting; Melting salts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/086—Cheese powder; Dried cheese preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/154—Milk preparations; Milk powder or milk powder preparations containing additives containing thickening substances, eggs or cereal preparations; Milk gels
- A23C9/1544—Non-acidified gels, e.g. custards, creams, desserts, puddings, shakes or foams, containing eggs or thickening or gelling agents other than sugar; Milk products containing natural or microbial polysaccharides, e.g. cellulose or cellulose derivatives; Milk products containing nutrient fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a peptide having an anti-oxidative action derived from milk protein, an antioxidant containing the peptide as an active ingredient, and an antioxidant food or drink or feed containing the peptide.
- the present invention also relates to a peptide having an adiponectin production promoting action derived from milk protein, an adiponectin production promoter containing the peptide as an active ingredient, and an adiponectin production promoting food or drink or feed containing the peptide.
- the present invention is an agent for promoting blood adiponectin concentration increase and Z or a decrease inhibitor containing an ingredient contained in cheese as an active ingredient, or for promoting blood adiponectin concentration increase and Z or a decrease containing a component contained in cheese. It relates to food and drink.
- highly unsaturated fatty acid-containing fats and oils, cheese and water are emulsified to prepare antioxidant emulsions to prevent oxidation of highly unsaturated fatty acid-containing fats and oils, fish odor and preservation derived from highly unsaturated fatty acid-containing fish oils
- a method for masking the off-flavor in the inside is disclosed (for example, see Patent Document 3).
- these are all highly unsaturated fatty acid-containing oils and fats that are emulsified by adding a water-soluble protein solution, a milk partial hydrolyzate, or cheese to a highly unsaturated fatty acid-containing oil. This prevents the fishy odor of the highly unsaturated fatty acid-containing oil itself and the unusual odor during storage.
- Adipose tissue the largest secretory tissue in the body, produces various endocrine factors and is involved in maintaining homeostasis in the body.
- Adipose tissue has been a powerful force that has only been considered a role as an energy storage so far
- adipose tissue secretes endocrine factors such as plasminogen activator monoinhibitor, tumor necrosis factor (TNF- ⁇ ), leptin, and adiponectin and contributes to the maintenance of homeostasis in the body.
- endocrine factors such as plasminogen activator monoinhibitor, tumor necrosis factor (TNF- ⁇ ), leptin, and adiponectin.
- Adiponectin one of the endocrine factors derived from adipose tissue, is a 30 kDa hormone consisting of 244 amino acids that promotes fat burning in the liver and muscles in addition to inhibiting arteriosclerosis. It is said to be effective. Adiponectin has also been shown to promote the uptake of glucose and fatty acids in the blood into cells. If fat accumulates in muscles or liver, sugar intake becomes worse, leading to diabetes. However, adiponectin is usually considered to maintain the nutritional balance in the body by breaking down excess fat and sugars temporarily. As it goes on, it is said that the function of fat cells that secrete adiponectin weakens and the nutritional balance in the body is lost.
- Adiponectin which is specifically secreted by adipose tissue, is usually present in a high concentration in blood, but it is known that secretion decreases as visceral fat accumulates. Adiponectin is known to have various physiological functions such as anti-diabetic, anti-arteriosclerosis, anti-inflammatory, and anti-hypertension, and promotes an increase in the concentration of adiponectin in the blood. Suppressing the reduction becomes very important in treating metabolic syndrome.
- adiponectin suppresses liver fibrosis and promotes normal hepatocyte proliferation and anti-inflammatory effects (see, for example, Patent Document 6), and as an adiponectin production promoter derived from food and drink,
- a composition for enhancing secretory protein in blood adipose tissue eg, patent document 7 containing a fermented tea extract, and a secretory protein specific to blood adipose tissue comprising an extract of a sub-tree of deciduous leaves belonging to the genus Komikansou called Amler And Patent Document 8).
- cheese is reported to have an effect of promoting a decrease in blood triglyceride concentration and an effect of improving cholesterol metabolism despite being a high-fat food.
- Reference 9, patent reference 10 what is known as a function of cheese is to promote an increase in blood adiponectin concentration or to suppress a decrease in blood adiponectin concentration.
- Patent Document 1 JP-A-60-102168
- Patent Document 2 JP-A-2-305898
- Patent Document 3 JP-A-7-274823
- Patent Document 4 JP-A-2004-352958
- Patent Document 5 Japanese Patent Application No. 2005-294358
- Patent Document 6 Japanese Unexamined Patent Publication No. 2000-256208
- Patent Document 7 Japanese Patent Application Laid-Open No. 2002-363094
- Patent Document 8 Japanese Unexamined Patent Publication No. 2006-56836
- Patent Document 9 Japanese Patent Laid-Open No. 2003-300890
- Patent Document 10 Japanese Patent Laid-Open No. 2003-144090
- Non-Patent Document 1 Nobuaki Tsuge et al., Japanese Journal of Agricultural Chemistry, 65, ⁇ .1635, 1991
- Non-Patent Literature 2 Etch 'HM' et al., Journal 'Agricultural' and 'Food' Chemistry, 43, p.574, 1995 Disclosure of the invention
- the present invention does not impair the flavor and nutritional value of foods, and in the living body not only cause deterioration of quality, but also prevents acidity and damage caused by active oxygen and free radicals that adversely affect diseases and aging. It is an object of the present invention to provide a peptide having an anti-acidic action that is effective for inhibition. Another object of the present invention is to provide a peptide that suppresses arteriosclerosis and promotes fat burning in the liver and muscles by promoting the production of adiponectin in the living body.
- the present invention is useful for promoting the increase of blood adiponectin concentration or suppressing the decrease of the concentration of adiponectin in the blood by ingesting it, and in addition, an ingredient contained in cheese that can be taken daily is an active ingredient.
- Providing blood adiponectin concentration increase and Z or decrease inhibitor, or blood adiponectin concentration increase and z or decrease inhibitor The task is to do.
- the present invention relates to a peptide having an antioxidant action consisting of an amino acid sequence represented by any one of the above formulas (1) to (3).
- the present invention also relates to a peptide having an anti-acidic action comprising an amino acid sequence represented by any one of formulas (1) to (3) derived from milk protein.
- the present invention also relates to an antioxidant comprising one or more peptides represented by any one of formulas (1) to (3) as an active ingredient.
- the present invention relates to a food or drink or feed for an acid koji that contains one or more peptides represented by any one of formulas (1) to (3).
- a peptide comprising the amino acid sequence represented by the above formula (1) has an effect of promoting the production of adiponectin, and has an effect at a low dose. It came to complete.
- the present invention relates to a peptide having an adiponectin production promoting action comprising the amino acid sequence represented by the above formula (1).
- the present invention also relates to a peptide having an adiponectin production promoting action comprising the amino acid sequence represented by the formula (1) derived from milk protein.
- the present invention also relates to an adiponectin production promoter comprising a peptide represented by formula (1) as an active ingredient.
- the present invention also relates to a food / beverage product or feed for promoting adiponectin production, which contains a peptide represented by formula (1).
- the present inventors have determined that the species of living organisms by food materials that can be ingested on a daily basis. From the viewpoint of preventing or improving various functional abnormalities, we have focused on the ingredients contained in cheese and confirmed its physiological function, which has the effect of promoting an increase in blood adiponectin concentration, or The present inventors have found an effect of suppressing a decrease in blood adiponectin concentration. Then, by using these physiological functions to promote blood adiponectin concentration increase and Z or decrease inhibitor, or food and drink for promoting blood adiponectin concentration increase and Z or decrease suppression, the blood adiponectin concentration can be increased. The present inventors have found that it is possible to promote or suppress a decrease in blood adiponectin concentration, and the present invention has been completed.
- a peptide having an anti-acidic action consisting of an amino acid sequence represented by any one of the formulas (1) to (3) of the present invention may cause deterioration in quality by impairing the flavor and nutritional value of food.
- it is effective in suppressing the oxidative damage of the living body caused by active oxygen and free radicals that adversely affect diseases and aging, and as an antioxidant containing this peptide as an active ingredient. It is useful as a food / drink for anti-acid koji or feed containing this peptide.
- a peptide having an adiponectin production promoting action consisting of the amino acid sequence represented by the formula (1) of the present invention is effective for promoting adiponectin production, and adiponectin production using this peptide as an active ingredient. It is useful as a promoter, and as a food or drink for promoting adiponectin production containing this peptide.
- the concentration of adiponectin in blood containing the active ingredient as an ingredient contained in the cheese of the present invention Food / beverage products that promote the increase in blood pressure and z or decrease, or promote the increase in blood adiponectin concentration and suppress z or decrease, promote the increase in blood adiponectin concentration and suppress Z or decrease by ingesting them. It suppresses excessive accumulation of visceral fat and is effective in the treatment and prevention of metabolic syndrome such as thrombosis, insulin resistance, abnormal glucose metabolism, and hypertension.
- FIG. 1 shows a separation chromatogram of a water-soluble peptide fraction made from gouda cheese (Example 1).
- FIG. 2 shows a separation chromatogram of a synthetic peptide fraction (Example 2).
- FIG. 3 shows the evaluation of antioxidant activity of synthetic peptide fractions (Example 2, Test Example 2).
- FIG. 4 shows a separation chromatogram of peptide fractions after trypsin digestion (Example 3).
- FIG. 5 shows the evaluation of antioxidative activity of peptide fractions after trypsin digestion (Example 3, Test Example 3).
- FIG. 6 shows adiponectin production (per unit of DNA) depending on the peptide concentration (Example 1, Test Example 4).
- FIG. 7 shows the amount of accumulated fat depending on the peptide concentration (Example 1, Test Example 4).
- FIG. 1 The arrow indicates the amino acid sequence of His-Pro-lie-Lys-His-Gin-Gly-Leu-Pro-Gin of the present invention.
- FIG. 4 In the figure, 1 shows the amino acid sequence of His-Pro-Ile-Lys of the present invention, and 2 in the figure shows the amino acid sequence of His-Gin-Gly-Leu-Pro-Gin of the present invention.
- Peptide digest 1 shows the amino acid sequence of His-Pro-Ile-Lys of the present invention
- peptide digest 2 shows the amino acid sequence of His-Gln-Gly-Leu-Pro-Gln of the present invention.
- the peptide comprising the amino acid sequence represented by can be obtained, for example, by suspending cheese in a solvent and then removing the insoluble material by degreasing and centrifugation. You can also remove the resulting fractional protein. Yes.
- suspending cheese in a solvent means that the solvent is added to the cheese and homogenized or crushed in the solvent so that the water-soluble peptide fraction is easily obtained.
- an aqueous solvent such as water or a phosphate buffer can be used. Thereafter, desalting may be performed using a dialysis membrane, ion exchange resin, or the like, or powder drying may be performed by lyophilization or spray drying.
- cheese ingredients for promoting growth and Z or decrease inhibitor and blood adiponectin concentration promotion and Z or decrease suppression foods and beverages include Parmesan cheese, Gruy Enole cheese, Maribo cheese, Gouda cheese, Cheddar cheese, Emmentanore.
- a fraction containing a peptide having an amino acid sequence ability represented by formulas (1) to (3) obtained by suspending cheese in a solvent and then degreasing, removing insoluble substances, and removing proteins is: Further purification by reverse phase chromatography using a C18 column is also possible.
- acidic conditions such as trifluoroacetic acid (TFA) or neutral conditions such as distilled water
- the fraction having antioxidant activity is not permeated to the column.
- the fraction that is adsorbed on the column and eluted with 80% acetonitrile is
- YMC-Pack ODS-A After dissolving the peptide-containing fraction with distilled water, YMC-Pack ODS-A Using a ram (4.6 mm X 150 mm; YMC), it is subjected to reverse phase HPLC to fractionate the peptides. Chromatography consists of a solvent (liquid A: 50 mM ammonium acetate aqueous solution; liquid B: 80% acetonitrile), concentration gradient (12% B ⁇ 60% B, 60 min), flow rate 0.8 ml / min, detection wavelength 215 nm. It is desirable to carry out under conditions.
- the peptide comprising the amino acid sequence represented by the formulas (1) to (3) and the fraction containing the peptide of the present invention can be used in food and drink products to prevent deterioration in the quality of the food and drink products.
- the peptide comprising the amino acid sequence represented by the formulas (1) to (3) and the fraction containing the peptide of the present invention can be used in food and drink products to prevent deterioration in the quality of the food and drink products.
- When blended in food and drink after grinding the cheese in water, remove the insoluble material by degreasing and centrifuging, and then mix the cheese water-soluble peptide obtained by removing the protein as it is.
- the peptide having the anti-acidic activity having amino acid sequence ability represented by the formulas (1) to (3) of the present invention and a fraction containing the peptide are administered orally or parenterally, It is possible to prevent the progression of diseases and aging by eliminating active oxygen, free radicals, and the like.
- the peptide having the adiponectin production promoting action comprising the amino acid sequence represented by the formula (1) of the present invention and the fraction containing the peptide are administered orally or parenterally to promote adiponectin production in the living body. By doing so, arteriosclerosis can be suppressed and fat burning in the liver and muscles can be promoted.
- the peptide of the present invention When administered orally or parenterally, the peptide of the present invention having an antioxidative action and adiponectin production promoting action, or an adiponectin concentration-increasing and Z or decrease inhibitor containing the ingredients contained in cheese as an active ingredient
- dosage forms include tablets, capsules, fine granules, powders, pills, troches, sublingual or liquid preparations, or parenteral administration preparations such as injections and suppositories. can do.
- the oral dose of a peptide having an action may be appropriately determined in consideration of the purpose of treatment and prevention, symptoms, body weight, age and sex, etc., but in general, formulas (1) to (3) per day for an adult )so
- the present invention is effective at low doses.
- the dosage of the adiponectin increase-promoting and Z- or decrease-inhibiting agent and the blood adiponectin increasing-promoting and Z- or decrease-inhibiting food or drink containing the components contained in the cheese of the present invention as the active ingredient is for therapeutic or preventive purposes.
- the peptide having the amino acid sequence ability represented by the formulas (1) to (3) of the present invention has an anti-acidic action or adenobiological in vivo by ingesting foods and drinks or feeds containing them. It also prevents the deterioration of foods and drinks mixed with foods and feeds, or the feed itself, due to acidification only by exerting an effect of promoting iponectin production.
- the blood adiponectin concentration increase promoting and Z or decrease inhibitor and the blood adiponectin concentration increasing promotion and Z or decrease suppressing food and drink according to the present invention have ingredients contained in cheese as active ingredients.
- the blood adiponectin concentration increase promoting and Z or decrease inhibitor or the food for promoting blood adiponectin increasing concentration and Z or decrease suppression of the present invention is the blood adiponectin concentration increasing promotion and z or decrease suppressing contained in cheese. Ingredients having use are blended.
- foods and drinks for promoting acid-acid koji or adiponectin production examples include butter, milk beverage, soft drink, juice, yogurt, jelly, bread, ice cream, rice cake, sausage, snack confectionery, cake, pudding, sausage, infant formula and baby food.
- the peptide having an anti-oxidative action consisting of the amino acid sequences represented by the formulas (1) to (3) of the present invention has only one peptide as an active ingredient and an antioxidant, It is possible to add only one kind to make food and drink or feed for anti-acid candy, but one or more of each peptide is an active ingredient It can also be used as an antioxidant, or it can be blended with one or more to produce a food or drink for feed or feed.
- This water-soluble peptide fraction was dissolved in distilled water and then subjected to reverse phase HPLC using a YMC-Pack ODS-A column (YMC; 4.6 mm X 150 mm) to fractionate into a water-soluble peptide purified fraction. . Chromatography is performed using solvent (A solution: 50 mM ammonium acetate aqueous solution; B solution: 80% acetonitrile), concentration gradient (12% B ⁇ 60% B, 60 min), flow rate 0.8 ml / min, detection wavelength 21 5 nm It went on condition of. The results are shown in Figure 1. When the antioxidant activity of the fractionated fraction was measured by the method of Test Example 1 shown below, strong antioxidant activity was confirmed in the fraction indicated by the arrow in the chromatogram.
- the peptide thus obtained can be used as it is as the antioxidant or the adiponectin production promoter of the present invention.
- Antioxidant activity of the peptide fractionated in Example 1 was measured by a method utilizing the action of an acid salt of linoleic acid to fade j8-carotene. That is, 0.5 ml of j8-carotene solution (lm g / ml black mouth form), 0.2 ml of linoleic acid solution (100 mg / ml black mouth form), 1.0 ml of Tween 40 solution (200 mg / ml black mouth form), 300 ml triangle The flask was placed in a flask and the chloroform was completely removed with nitrogen gas, and then 100 ml of distilled water was added and dissolved.
- Anti-acid activity is substituted into the following formula and expressed as anti-acid ratio (%)
- carnosin ⁇ -Ala-L-His; Peptide Institute
- a muscle-derived antioxidative peptide was prepared at 0.01 ⁇ g / ml, 0.1 ⁇ g / ml, and 1 ⁇ g. The one prepared to / ml was used.
- Table 1 shows the results of measuring the anti-acid activity of purified peptide and carnosine as a positive control.
- the peptide derived from cheese with the amino acid sequence represented by His-Pro-Ile-Lys-His-Gln-Gly-Leu-Pro-Gln has anti-acid activity (radical strength). It was proved that it is useful for the prevention and improvement of oxidative cell damage caused by active oxygen and lipid peroxide.
- the peptide having the amino acid sequence ability represented by the above formula (1) was synthesized with a peptide synthesizer.
- Peptide synthesizer 431 A (Applied Biosystems) using parahydroxymethylphenoxymethylpolystyrene (HMP) resin and the 9 fluorenylmethyloxycarboxyl (Fmoc) group at the amino terminal
- HMP parahydroxymethylphenoxymethylpolystyrene
- Fmoc 9 fluorenylmethyloxycarboxyl
- the obtained HMP-resin-binding protected peptide was simultaneously cleaved from the HMP-resin and removed the protecting group with trifluoroacetic acid (TFA). After removing TFA by vacuum concentration, the crude peptide was crystallized with ethyl ether, dissolved in 5% acetic acid, and lyophilized.
- TFA trifluoroacetic acid
- the obtained linear crude peptide was subjected to HPLC using a YMC-Pack ODS-A column (YMC; 4.6 mm ⁇ 150 mm). Chromatography consists of solvent (solution A: 50 mmol ammonium acetate aqueous solution; solution B: 80% acetonitrile), concentration gradient (12% B ⁇ 60% B, 60 min), flow rate 0.8 ml / min, detection wavelength 215. Performed under conditions. The purity of the obtained linear purified peptide was 98% as a result of analysis by HPLC. The result is shown in figure 2.
- the peptide thus obtained can be used as it is as the antioxidant or the adiponectin production promoter of the present invention.
- Antioxidant activity was measured for the peptide obtained in Example 2 in the same manner as in Test Example 1.
- carnosine j8-Ala-L-His; Peptide Research Laboratories
- catechin Wako Pure Chemical Industries, Ltd.
- muscle-derived anti-acidic active peptides were adjusted to 1 m, lO ⁇ m, 100 m. The prepared one was used.
- the results of evaluating the anti-acid activity of the synthetic peptide are shown in Table 2 and FIG. As shown in Table 2 and FIG. 3, strong antioxidative activity was confirmed in the obtained synthetic peptide.
- a tryptic digest of the peptide obtained in Example 2 was prepared.
- the enzyme reaction solution (50 mM Tris-HC1, 20 mM CaCl, pH 8.0) was prepared so that the peptide obtained in Example 2 and trypsin (Sigma Aldrich Japan) were each lmg / ml.
- This trypsin digest was dissolved in distilled water and then subjected to HPLC using a YMC-Pack ODS-A column (YMC; 4.6 mm ⁇ 150 mm). HPLC analysis was performed under the same conditions as the peptide before digestion with trypsin in Example 2. The results are shown in Fig. 4. As shown in the figure, it was divided into two peaks.
- the thus obtained peptide having anti-oxidative activity can be used as it is as the antioxidant of the present invention.
- Antioxidant activity was measured using the carotene bleaching method in the same manner as in Test Example 2 for the two peptides that were trypsin digests obtained in Example 3 and the trypsin digest before fractionation.
- the peptide concentration was measured by dissolving each peptide in 500 ⁇ l of pure water and using Micro BCA Protein assay kit (Pierce).
- carnosine / 3-Ala-L-His; Peptide Institute
- catechin Wako Pure Chemical Industries, Ltd.
- FIG. 5 shows the results of evaluating the anti-acid activity of tryptic peptides. As shown in Figure 5, the resulting trypsin digestion peptide is strong! ⁇ Antioxidant activity was confirmed.
- the peptide isolated from the cheese obtained in Example 1 was administered to primary cultured visceral fat cells.
- GPDH glycerol 3-phosphate dehydrogenase
- the amount of DNA was quantified using a DNA quantification kit manufactured by Cell Garage.
- Intracellular glycerol 3-phosphate dehydrogenase (GPDH) enzyme activity was measured using a cell garage GPDH activity measurement kit according to the Cell Garage protocol. The measurement results were standardized by the amount of DNA extracted from each well.
- GPDH Intracellular glycerol 3-phosphate dehydrogenase
- the adiponectin concentration was measured using an adiponectin ELISA kit manufactured by Otsuka Pharmaceutical Co., Ltd. The measurement results were standardized by the amount of DNA extracted from each well force.
- the amount of accumulated fat in the cells was determined by fat staining with Oil Red 0 and quantification of the accumulated fat by absorbance measurement using a fat staining kit manufactured by Cell Garage.
- the Student's t-test showed that no significant difference was detected in the amount of cellular DNA between the group to which the peptide of the present invention was not added and the group to which the peptide was added.
- GPDH activity per unit amount of DNA
- GPDH activity normalized by the amount of cellular DNA in each well showed significantly higher activity in the 10 M or 50 M addition group of the peptide of the present invention than in the no peptide addition group. It was. No significant difference was detected between the peptide 100 M addition group and the non-addition group.
- Figure 6 shows the difference in adiponectin production (per unit of DNA) due to the difference in the administered peptide concentration on the seventh day when the concentration of adiponectin in the culture supernatant was the highest.
- the adiponectin concentration increase promotion and Z or decrease suppression action in the present invention
- the active ingredient is not limited to these peptides, but may contain various other active ingredients.
- the peptide-anchored promoter promotes the differentiation of preadipocytes into adipocytes, or promotes the fat synthesis activity in differentiated mature adipocytes.
- the synthesized fat may be broken down by some other molecular mechanism.
- Adiponectin is a good cytosite in which mature adipocyte force is also secreted, and this adiponectin production promoting effect was confirmed by the peptide-added kit of the present invention. From the above, it is recognized that the peptide of the present invention has an effect of promoting functional differentiation into adipocyte power adipocytes and increasing the production of adiponectin. It was suggested that there might be an inhibitory effect.
- Adiponectin is said to have the effect of promoting fat burning in the liver and muscles, in addition to inhibiting arteriosclerosis.
- the peptide of the present invention has the function of preventing adipose syndrome by producing adipocytes that are likely to produce adiponectin. You could think so.
- the effect of the peptide of the present invention on adipocytes varies depending on the concentration, suggesting the possibility that an optimal concentration exists.
- the effect of promoting the production of adiponectin was confirmed by the peptide-added kit of the present invention.
- the peptide of the present invention which must have an effect of suppressing the amount of accumulated fat, has a metabolic syndrome preventing effect.
- His-Pro-Ile-Lys-His-Gln-Gly-Leu-Pro-Gln is a trypsin degradation product of the peptide consisting of the amino acid sequence represented by His-Pro-Ile-Lys-His-Gln-Gly-Leu-Pro-Gln. It was confirmed that the peptide having the amino acid sequence ability represented by -Leu-Pro-Gln has the same effect of promoting adiponectin production.
- the raw milk was sterilized by heating (75 ° C for 15 seconds), cooled to 30 ° C, and 0.01% salt calcium was added.
- commercially available lactic acid bacteria starter for cheese production (Christian 'Hansen) 1.5% and polysaccharide-producing lactic acid bacteria L. helveticus SBT21 71 ( ⁇ -14381) 3 0 / ( ⁇ 3 ⁇ 4 ⁇ , rennet
- the milk was coagulated by adding 0.003%, and the curd thus obtained was cut and stirred until ⁇ 6.2 reached 6.2 to 6.1 to discharge whey to obtain curd grains.
- the curd grains were molded, squeezed, further salted, and aged at 10 ° C to prepare gouda cheese type hard natural cheese.
- This hard natural cheese (aged for 12 months) was minced. (GM-DX, manufactured by Nippon Carrier Co., Ltd.) Minced and freeze-dried, then refined with a coffee mill to obtain cheese powder.
- Example 5 (Confirmation of blood adiponectin concentration increase promotion and z or decrease inhibitory action) Using the cheese powder obtained in Example 4, blood adiponectin concentration increase promotion and Z or decrease suppressive action was confirmed.
- Animal experiments consisted of 8 animals per group, a group administered with a high fat diet containing cheese powder (a cheese diet group), a group administered with a control diet without administering a high fat diet formulated with cheese powder (a control diet group) )
- the control feed contains the general ingredients, main minerals, vitamin E-tocopherol) in a high-fat feed containing cheese flour, Milk casein and butter oil were used as the lipid source.
- both protein and lipid were covered with only cheese components.
- a control diet was fed up to 4 weeks after breeding, and then divided into two groups, and a control diet or a high fat diet formulated with cheese powder was fed up to 8 weeks.
- Blood was collected at 4 weeks and 8 weeks, and the blood adiponectin concentration was measured using mouse Z rat adiponectin ELISA kit (manufactured by Otsuka Pharmaceutical Co., Ltd.).
- blood triglyceride concentration and blood total cholesterol concentration at 8 weeks were measured.
- Adiponectin concentration in blood (ix g / ml)
- Each component was mixed with the composition shown in Table 6, filled into a container, and then heat-sterilized, and then the synthetic antioxidant peptide (His-Pro-Ile-Lys-His-Gln) obtained in Example 2 of the present invention was used. -Gly-Leu-Pro- The fruit juice beverage for anti-acid koji of the present invention containing Gin) was produced.
- Antioxidant peptide His ⁇ Gln- Gly-Leu_Pro- Gin
- Example 3 of the present invention His-Gln-Gly-Leu-Pro-Gln and An anti-acid soft drink of the present invention containing His-Pro-Ile-Lys was produced.
- a dough having the composition shown in Table 9 was prepared, molded, and then baked to obtain the peptide obtained in Example 1 of the present invention (His-Pro-lie-Lvs-His-Gln-Gly-Leu-Pro-Gin). ) And the antioxidant biscuits of the present invention were produced.
- a feed for breeding dogs according to the present invention containing (His-Pro-Ile-Lys-His-Gln-Gly-Leu-Pro-Gin) was produced.
- Antioxidant peptide obtained in Example 1 (His-Pro-Ile-Lys-His-Gln-Gly-Leu-Pro-Gln) 20% by weight, lactose (DMV) 46% by weight, crystalline cellulose (Wako Pure Chemicals) (Industry Co., Ltd.) 31% by weight and 3 parts by weight of water were sufficiently mixed, and then tableted with a tableting machine (Fuji Pharmaceutical Co., Ltd.) to produce the tablet for promoting adiponectin production of the present invention.
- a tableting machine Fruji Pharmaceutical Co., Ltd.
- Example 2 of the present invention Each component was mixed with the composition shown in Table 11, filled into a container, and then heat-sterilized, and then the synthetic peptide (His-Proly-Lys-His-Gin-Gly) obtained in Example 2 of the present invention was used.
- -A fruit juice drink for promoting adiponectin production according to the present invention containing Leu-Pro-Gin) was produced.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Birds (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07742361.4A EP2017283A4 (en) | 2006-04-28 | 2007-04-25 | Peptides |
CN2007800154883A CN101432295B (zh) | 2006-04-28 | 2007-04-25 | 来自乳蛋白质的肽的应用 |
KR1020137030933A KR20130140215A (ko) | 2006-04-28 | 2007-04-25 | 펩티드 |
NZ572152A NZ572152A (en) | 2006-04-28 | 2007-04-25 | Peptidethat is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agen |
AU2007244352A AU2007244352B2 (en) | 2006-04-28 | 2007-04-25 | Peptide |
US12/298,190 US8207131B2 (en) | 2006-04-28 | 2007-04-25 | Peptide |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-126103 | 2006-04-28 | ||
JP2006126103A JP2007254449A (ja) | 2006-02-22 | 2006-04-28 | 脂質改善剤 |
JP2006-125283 | 2006-04-28 | ||
JP2006125283A JP4870469B2 (ja) | 2006-02-24 | 2006-04-28 | ペプチド |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007125946A1 true WO2007125946A1 (ja) | 2007-11-08 |
Family
ID=38655472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/058926 WO2007125946A1 (ja) | 2006-04-28 | 2007-04-25 | ペプチド |
Country Status (7)
Country | Link |
---|---|
US (1) | US8207131B2 (ja) |
EP (1) | EP2017283A4 (ja) |
KR (2) | KR20090009862A (ja) |
CN (1) | CN101432295B (ja) |
AU (1) | AU2007244352B2 (ja) |
NZ (2) | NZ594814A (ja) |
WO (1) | WO2007125946A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2567959A1 (en) | 2011-09-12 | 2013-03-13 | Sanofi | 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN110283234A (zh) * | 2019-08-01 | 2019-09-27 | 四川旅游学院 | 一种源于牦牛血的抗氧化肽及其制剂和应用 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5188731B2 (ja) * | 2007-03-02 | 2013-04-24 | 雪印メグミルク株式会社 | ペプチド |
US9345727B2 (en) | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component and uses thereof |
US8889633B2 (en) | 2013-03-15 | 2014-11-18 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof |
US9289461B2 (en) | 2013-03-15 | 2016-03-22 | Mead Johnson Nutrition Company | Reducing the risk of autoimmune disease |
US9138455B2 (en) * | 2013-03-15 | 2015-09-22 | Mead Johnson Nutrition Company | Activating adiponectin by casein hydrolysate |
US9345741B2 (en) * | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof |
US9352020B2 (en) | 2013-03-15 | 2016-05-31 | Mead Johnson Nutrition Company | Reducing proinflammatory response |
WO2020050427A1 (ko) * | 2018-09-03 | 2020-03-12 | (주)정진호이펙트 | 아디포넥틴 유래 펩티드 및 이를 포함하는 피부노화 방지 또는 피부주름 개선용 조성물 |
CN112587439B (zh) * | 2020-12-16 | 2022-11-15 | 中科南京绿色制造产业创新研究院 | 一种抗氧化肽组合物及其制备方法和应用 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60102168A (ja) | 1983-11-08 | 1985-06-06 | Tsukishima Shokuhin Kogyo Kk | エイコサペンタエン酸強化乳化物及び食品の製造方法 |
JPH02305898A (ja) | 1989-05-19 | 1990-12-19 | Sankyo Shokuhin Kogyo Kk | 高度不飽和脂肪酸含有油脂の粉末とその製造方法 |
JPH07274823A (ja) | 1994-04-04 | 1995-10-24 | Snow Brand Milk Prod Co Ltd | 抗酸化性乳化物、それを含有した飲食物、およびその製造方法 |
JP2000256208A (ja) | 1999-03-09 | 2000-09-19 | Univ Osaka | 抗炎症剤、単球系細胞の増殖抑制剤 |
JP2002363094A (ja) | 2001-06-07 | 2002-12-18 | Yuji Matsuzawa | 肝線維化抑制剤 |
JP2003144090A (ja) | 2001-11-13 | 2003-05-20 | Meiji Milk Prod Co Ltd | コレステロール代謝改善作用を有するチーズ及び該チーズ添加食品 |
JP2003300890A (ja) | 2002-04-08 | 2003-10-21 | Snow Brand Milk Prod Co Ltd | 血中トリグリセリド濃度低下剤 |
JP2004352958A (ja) | 2003-05-30 | 2004-12-16 | Snow Brand Milk Prod Co Ltd | 抗酸化剤 |
WO2005081628A2 (en) * | 2004-03-01 | 2005-09-09 | Peptera Pharmaceutical Ltd. | Casein derived peptides and therapeutic uses thereof |
JP2005294358A (ja) | 2004-03-31 | 2005-10-20 | Tdk Corp | インダクタ |
US20050281914A1 (en) * | 2003-06-20 | 2005-12-22 | Steele James L | Methods and compositions involving endopeptidases PepO2 and PepO3 |
JP2006056836A (ja) | 2004-08-20 | 2006-03-02 | Taiyo Kagaku Co Ltd | 脂肪組織特異分泌蛋白産生増強組成物 |
WO2006068480A2 (en) * | 2004-12-23 | 2006-06-29 | Campina Nederland Holding B.V. | Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6426102B1 (en) * | 2000-07-18 | 2002-07-30 | Kraft Foods Holdings, Inc. | Shredded cheese |
JP2005060308A (ja) | 2003-08-13 | 2005-03-10 | National Institute Of Advanced Industrial & Technology | アディポネクチンの産生増強、促進剤 |
-
2007
- 2007-04-25 WO PCT/JP2007/058926 patent/WO2007125946A1/ja active Application Filing
- 2007-04-25 EP EP07742361.4A patent/EP2017283A4/en not_active Withdrawn
- 2007-04-25 KR KR1020087027775A patent/KR20090009862A/ko not_active Application Discontinuation
- 2007-04-25 CN CN2007800154883A patent/CN101432295B/zh not_active Expired - Fee Related
- 2007-04-25 NZ NZ594814A patent/NZ594814A/xx not_active IP Right Cessation
- 2007-04-25 AU AU2007244352A patent/AU2007244352B2/en not_active Ceased
- 2007-04-25 NZ NZ572152A patent/NZ572152A/en not_active IP Right Cessation
- 2007-04-25 KR KR1020137030933A patent/KR20130140215A/ko not_active Application Discontinuation
- 2007-04-25 US US12/298,190 patent/US8207131B2/en not_active Expired - Fee Related
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60102168A (ja) | 1983-11-08 | 1985-06-06 | Tsukishima Shokuhin Kogyo Kk | エイコサペンタエン酸強化乳化物及び食品の製造方法 |
JPH02305898A (ja) | 1989-05-19 | 1990-12-19 | Sankyo Shokuhin Kogyo Kk | 高度不飽和脂肪酸含有油脂の粉末とその製造方法 |
JPH07274823A (ja) | 1994-04-04 | 1995-10-24 | Snow Brand Milk Prod Co Ltd | 抗酸化性乳化物、それを含有した飲食物、およびその製造方法 |
JP2000256208A (ja) | 1999-03-09 | 2000-09-19 | Univ Osaka | 抗炎症剤、単球系細胞の増殖抑制剤 |
JP2002363094A (ja) | 2001-06-07 | 2002-12-18 | Yuji Matsuzawa | 肝線維化抑制剤 |
JP2003144090A (ja) | 2001-11-13 | 2003-05-20 | Meiji Milk Prod Co Ltd | コレステロール代謝改善作用を有するチーズ及び該チーズ添加食品 |
JP2003300890A (ja) | 2002-04-08 | 2003-10-21 | Snow Brand Milk Prod Co Ltd | 血中トリグリセリド濃度低下剤 |
JP2004352958A (ja) | 2003-05-30 | 2004-12-16 | Snow Brand Milk Prod Co Ltd | 抗酸化剤 |
US20050281914A1 (en) * | 2003-06-20 | 2005-12-22 | Steele James L | Methods and compositions involving endopeptidases PepO2 and PepO3 |
WO2005081628A2 (en) * | 2004-03-01 | 2005-09-09 | Peptera Pharmaceutical Ltd. | Casein derived peptides and therapeutic uses thereof |
JP2005294358A (ja) | 2004-03-31 | 2005-10-20 | Tdk Corp | インダクタ |
JP2006056836A (ja) | 2004-08-20 | 2006-03-02 | Taiyo Kagaku Co Ltd | 脂肪組織特異分泌蛋白産生増強組成物 |
WO2006068480A2 (en) * | 2004-12-23 | 2006-06-29 | Campina Nederland Holding B.V. | Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use |
Non-Patent Citations (4)
Title |
---|
CHEN, H.M. ET AL., J. AGRIC. FOOD CHEM., vol. 43, 1995, pages 574 |
HIGURE S. ET AL.: "Cheese no Naizo Shibo Chikuseki Yokusei Sayo oyobi Adiponectin Teika Yokusei Sayo", THE JAPANESE SOCIETY OF NUTRITION AND FOOD SCIENCE TAIKAI KOEN YOSHISHU, vol. 60TH, 1 April 2006 (2006-04-01), pages 353 + ABSTR. NO. 3H-14P, XP003018949 * |
KUNIEDA Y. ET AL.: "Gouda Cheese Yurai Kosanka Peptide no Bunri to Dotei", JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY 2006 NENDO (HEISEI 18 NENDO) TAIKAI KOEN YOSHISHU, 5 March 2006 (2006-03-05), pages 69 + ABSTR. NO. 2J15P20, XP003018950 * |
TSUGE, N ET AL., NIPPON NOGEIKAGAKU KAISHI, vol. 65, 1991, pages 1635 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2567959A1 (en) | 2011-09-12 | 2013-03-13 | Sanofi | 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN110283234A (zh) * | 2019-08-01 | 2019-09-27 | 四川旅游学院 | 一种源于牦牛血的抗氧化肽及其制剂和应用 |
CN110283234B (zh) * | 2019-08-01 | 2022-11-29 | 四川旅游学院 | 一种源于牦牛血的抗氧化肽及其制剂和应用 |
Also Published As
Publication number | Publication date |
---|---|
AU2007244352B2 (en) | 2013-09-26 |
KR20090009862A (ko) | 2009-01-23 |
EP2017283A1 (en) | 2009-01-21 |
NZ572152A (en) | 2012-07-27 |
KR20130140215A (ko) | 2013-12-23 |
EP2017283A4 (en) | 2015-12-30 |
CN101432295B (zh) | 2013-01-30 |
US20100075909A1 (en) | 2010-03-25 |
CN101432295A (zh) | 2009-05-13 |
NZ594814A (en) | 2013-03-28 |
AU2007244352A1 (en) | 2007-11-08 |
US8207131B2 (en) | 2012-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007125946A1 (ja) | ペプチド | |
WO2007138749A1 (ja) | 内臓脂肪蓄積抑制剤及び、血中アディポネクチン濃度増加促進及び/又は減少抑制剤 | |
TW200836640A (en) | Method of separating fat from soy materials and compositions produced therefrom | |
WO2007116981A1 (ja) | 脂肪蓄積抑制剤 | |
JP2010018522A (ja) | アディポネクチン産生促進剤 | |
JP4870469B2 (ja) | ペプチド | |
JP5972235B2 (ja) | 血中トリグリセライド低下剤 | |
JP5229977B2 (ja) | 血中アディポネクチン濃度増加促進及び/又は減少抑制剤 | |
JP4210158B2 (ja) | 抗酸化剤 | |
JP4899147B2 (ja) | ペプチド | |
JP2008088151A (ja) | 醤油に含まれる高分子物質の用途 | |
JP5635765B2 (ja) | 生活習慣病予防又は改善剤 | |
JP2007254449A (ja) | 脂質改善剤 | |
JP4750213B1 (ja) | アディポネクチン産生促進組成物 | |
JP5177778B2 (ja) | ペプチド | |
JP5295581B2 (ja) | 内臓脂肪蓄積抑制剤 | |
JP4845102B2 (ja) | ペプチド | |
JP5871330B2 (ja) | ペプチド | |
JP2012056879A (ja) | アンジオテンシン変換酵素阻害剤およびその用途 | |
JP7376335B2 (ja) | 脂質異常症の予防、改善又は治療用組成物 | |
JPWO2006101181A1 (ja) | 肝機能障害予防もしくは改善組成物、及び肝機能障害予防もしくは改善法 | |
JP5344669B2 (ja) | 内臓脂肪蓄積抑制剤 | |
JP2007223926A (ja) | 内臓脂肪蓄積抑制剤 | |
JP5950395B2 (ja) | 卵白アルブミン分解物を含有する脂質代謝改善剤 | |
JPWO2004009107A1 (ja) | 体脂肪低減剤又は体脂肪増加抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07742361 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007244352 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 572152 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780015488.3 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007244352 Country of ref document: AU Date of ref document: 20070425 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087027775 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007742361 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12298190 Country of ref document: US |